Carlos Cruchaga, PhD, director of the NeuroGenomics and Informatics Center at Washington University, discusses emerging blood-based biomarkers for monitoring biological and cognitive responses to lecanemab treatment in Alzheimer disease.
Carlos Cruchaga, PhD
Advertisement
Articles by Carlos Cruchaga, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
12-Month Gluten-Free Diet Linked to Cognitive, Quality-of-Life Improvements in Parkinson Disease
2
GLP-1/GIP Agonist KP405 Shows Biomarker Signal in Parkinson Disease
3
LRRK2 Inhibitor BIIB122 Fails to Slow Early-Stage Parkinson Disease
4
Phase 1 Data Link ARV-102 LRRK2 Degradation to Oculomotor and CSF Biomarker Changes in Parkinson Disease
5